Biomaterial-based antimicrobial therapies for the treatment of bacterial infections

PP Kalelkar, M Riddick, AJ García - Nature Reviews Materials, 2022 - nature.com
The rise in antibiotic-resistant bacteria, including strains that are resistant to last-resort
antibiotics, and the limited ability of antibiotics to eradicate biofilms have necessitated the …

Antibiotic resistance and persistence—Implications for human health and treatment perspectives

M Huemer, S Mairpady Shambat, SD Brugger… - EMBO …, 2020 - embopress.org
Antimicrobial resistance (AMR) and persistence are associated with an elevated risk of
treatment failure and relapsing infections. They are thus important drivers of increased …

Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review

MS Mulani, EE Kamble, SN Kumkar… - Frontiers in …, 2019 - frontiersin.org
The acronym ESKAPE includes six nosocomial pathogens that exhibit multidrug resistance
and virulence: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae …

Catheter-associated urinary tract infections: current challenges and future prospects

GT Werneburg - Research and reports in urology, 2022 - Taylor & Francis
Catheter-associated urinary tract infection (CAUTI) is the most common healthcare-
associated infection and cause of secondary bloodstream infections. Despite many …

Considerations and caveats in combating ESKAPE pathogens against nosocomial infections

YX Ma, CY Wang, YY Li, J Li, QQ Wan… - Advanced …, 2020 - Wiley Online Library
ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter …

Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double …

L Leitner, A Ujmajuridze, N Chanishvili… - The Lancet Infectious …, 2021 - thelancet.com
Summary Background Urinary tract infections (UTIs) are among the most prevalent microbial
diseases and their financial burden on society is substantial. In the context of increasing …

Bacteriophage therapy: clinical trials and regulatory hurdles

LL Furfaro, MS Payne, BJ Chang - Frontiers in cellular and infection …, 2018 - frontiersin.org
Increasing reports of antimicrobial resistance and limited new antibiotic discoveries and
development have fuelled innovation in other research fields and led to a revitalization of …

Translating phage therapy into the clinic: Recent accomplishments but continuing challenges

A Petrovic Fabijan, J Iredell, K Danis-Wlodarczyk… - Plos …, 2023 - journals.plos.org
Phage therapy is a medical form of biological control of bacterial infections, one that uses
naturally occurring viruses, called bacteriophages or phages, as antibacterial agents …

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

B Isler, Y Doi, RA Bonomo… - Antimicrobial agents and …, 2019 - Am Soc Microbiol
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen
causing substantial morbidity and mortality. Current treatment options for CRAB are limited …

Current clinical landscape and global potential of bacteriophage therapy

NM Hitchcock, D Devequi Gomes Nunes, J Shiach… - Viruses, 2023 - mdpi.com
In response to the global spread of antimicrobial resistance, there is an increased demand
for novel and innovative antimicrobials. Bacteriophages have been known for their potential …